Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

CRSP CRISPR Therapeutics AG

-1.50 (-2.47%)
Last Updated: 14:12:45
Delayed by 15 minutes


Draw Mode:

Volume 926,998
Bid Price 59.13
Ask Price 59.17
News -
Day High 60.95


52 Week Range


Day Low 58.91
Company Name Stock Ticker Symbol Market Type
CRISPR Therapeutics AG CRSP NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-1.50 -2.47% 59.17 14:12:45
Open Price Low Price High Price Close Price Prev Close
60.74 58.91 60.95 60.67
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
17,521 926,998 $ 59.78 $ 55,414,983 - 37.55 - 91.10
Last Trade Time Type Quantity Stock Price Currency
14:12:45 77 $ 59.16 USD

CRISPR Therapeutics (CRSP) Options Flow Summary

Overall Flow


Net Premium


Calls / Puts


Buys / Sells




Sweeps Ratio


CRISPR Therapeutics AG Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
4.74B 80.28M - 371.21M -153.61M -1.91 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

CRISPR Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No CRSP Message Board. Create One! See More Posts on CRSP Message Board See More Message Board Posts

Historical CRSP Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week63.2165.2458.9162.741,236,068-4.04-6.39%
1 Month73.4275.9158.9167.411,226,914-14.25-19.41%
3 Months62.4691.1058.9174.241,791,320-3.29-5.27%
6 Months44.3191.1037.5565.262,356,61914.8633.54%
1 Year50.8291.1037.5561.891,745,6398.3516.43%
3 Years125.00169.6737.5571.991,503,159-65.83-52.66%
5 Years38.00220.2132.0080.531,343,02521.1755.71%

CRISPR Therapeutics Description

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Your Recent History

Delayed Upgrade Clock